市场概况

The market for therapeutics to treat Crohn’s disease is projected to grow at a CAGR of 7.6% 从 2023 到 2029, 达到美元 23.63 十亿 2029, compared to USD 13.86 十亿 2022. Crohn’s disease, an inflammatory bowel disease, causes digestive tract inflammation and symptoms like abdominal pain, severe diarrhea, and weight loss. The market is dominated by Crohn’s disease in the inflammatory bowel disease treatment sector. The US has the highest prevalence of Crohn’s disease, followed by the UK and China. The rising prevalence drives the market’s growth. Over 100 assets are in development for Crohn’s disease, with most in Phase II. Anti-interleukin and integrin antibodies are the primary drugs in the pipeline. The US leads in global clinical trials. 抗TNF之类的生物制剂被广泛使用, 但是需要具有更好的动作和便利机制的新疗法. 基于微生物组的治疗剂表现出承诺. 主要公司投资研究, 收购, 和合作. 已经推出了多种疗法, 包括Humira, Remicade, 和Stelara. 五家主要公司批准了克罗恩病的药物.

该报告涵盖了市场规模和增长, 分割, 竞争格局, 全球克罗恩病治疗市场的趋势和策略. 它提供了对市场的定量分析，使利益相关者能够利用当前的市场机会. 该报告还根据市场趋势和主要竞争对手的方法确定了最重要的机会和战略细分市场.

市场细分

市场根据多种因素进行细分, 包括毒品类, 性别类型, 年龄阶层, 疾病类型, 和地理.
毒品类: 5-氨基水杨酸盐, TNF-α抑制剂, 其他的
性别: 男人, 女性
年龄阶层: 49 一年. & 以下, 50 一年. & 多于
疾病类型: 大肠类型, 小肠道, 小/大肠道

按地理位置细分
北美 – 美国
欧洲 - 德国, 法国, 英国, 意大利, 西班牙
亚太地区 – 中国, 日本

TNF-Alpha抑制剂在全球克罗恩病治疗市场中占有重要份额, 但是其他药物类别预计将迅速增长. Skyrizi的批准将推动市场. New mechanisms of action are being researched to address non-response issues. Launch of new drugs for moderate-to-severe patients will contribute to market growth. Anti-integrin and interleukin inhibitors gain popularity. Women have a substantial presence. The small intestinal type grows fastest. Individuals aged 49 and below dominate. The US dominates, but the UK will grow rapidly. Biosimilars impact China and Japan.

竞争格局

The Crohn’s disease treatment market is dominated by generic medication providers and selective pharmaceutical and biotechnology companies. Key companies in this market include AbbVie Inc., 阿斯利康公司, Biogen Inc., 勃林格殷格翰国际有限公司, 百时美施贵宝公司, Celltrion, 公司, 约翰逊 & 约翰逊 (J&J), Redhill Biopharma Ltd., 武田制药有限公司, UCB SA, 除其他外.

最新行业发展

AbbVie achieved a significant milestone in June 2022 with the FDA approval of SKYRIZI (risankizumab-rzaa), the first and only IL-23 inhibitor for moderately to severely active Crohn’s disease (光盘). The approval was based on positive results from the ADVANCE and MOTIVATE studies, which evaluated risankizumab’s efficacy and safety in comparison to placebo.

在五月 2022, AbbVie announced positive topline results from the Phase 3 U-ENDURE maintenance study, showing that upadacitinib demonstrated superior efficacy compared to placebo in achieving endoscopic response and clinical remission in patients with moderate to severe Crohn’s disease.

Ossium Health received FDA acceptance of its IND application for OSSM-001 in March 2022. OSSM-001, a mesenchymal stem cell product, aims to treat refractory perianal fistulas in Crohn’s disease patients. Ossium is now preparing for a Phase 1 评估OSSM的安全性和功效的临床试验-001, 预计将在结束时开始 2022.

报告范围

分析和预测全球克罗恩病疗法市场的市场规模.
根据药物类别对全球克罗恩病治疗药物进行分类和预测, 性别, 年龄阶层, 疾病类型, 地理.
确定全球克罗恩病疗法市场的驱动因素和挑战.
检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, 在全球克罗恩病疗法市场中.
识别和分析在全球克罗恩病治疗市场中运作的领先参与者的概况.

为什么选择这份报告

从全球克罗恩病治疗药物市场预测中获得可靠的前景 2023 到 2029 跨场景.
确定投资的增长领域.
通过公司简介和市场数据领先于竞争对手.
Excel 格式的跨场景分析易用性的市场预估.
三个月的战略咨询和研究支持.
为单用户许可证提供打印验证.